U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H22N6O2.2ClH.H2O
Molecular Weight 505.3977
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE

SMILES

c1cc(ccc1-c2ccnc(Nc3ccc(cc3)N4CCOCC4)n2)C(=O)NCC#N.Cl.Cl.O

InChI

InChIKey=RQKCPSIFARJBOR-UHFFFAOYSA-N
InChI=1S/C23H22N6O2.2ClH.H2O/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;;;/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);2*1H;1H2

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C23H22N6O2
Molecular Weight 414.4607
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/19295546 | https://www.ncbi.nlm.nih.gov/pubmed/23459451

Momelotinib (CYT387) is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases. Momelotinib is developing by Gilead Sciences for the oral treatment of pancreatic and non-small cell lung cancers, and myeloproliferative disorders (including myelofibrosis, essential thrombocythaemia and polycythaemia vera).

CNS Activity

Curator's Comment:: Momelotinib (CYT387) is brain penetrant in mice. No human data available.

Approval Year

PubMed

PubMed

TitleDatePubMed
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
2009 Aug
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
2009 Oct 15
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
2010 Jun 24
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
2013 Jun
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
2014 Apr
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
2014 May 6
Patents

Sample Use Guides

150-300 mg/day. Maximum tolerated dose of momelotinib was found to be 300 mg/day in the phase I portion of a phase I/II study (NCT00935987) in patients with myelofibrosis. At the higher dose level of 400 mg/day, two of six patients experienced dose-limiting toxicities.
Route of Administration: Oral
0.5 and 1.5 uM CYT387 caused growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines, while nonhematopoietic cell lines were unaffected.
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:55:49 UTC 2021
Edited
by admin
on Sat Jun 26 03:55:49 UTC 2021
Record UNII
LDX8893L5D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
Common Name English
CYT-387 DIHYDROCHLORIDE MONOHYDRATE
Code English
BENZAMIDE, N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-, HYDROCHLORIDE, HYDRATE (1:2:1)
Systematic Name English
CYT-11387 DIHYDROCHLORIDE MONOHYDRATE
Code English
Code System Code Type Description
PUBCHEM
102514733
Created by admin on Sat Jun 26 03:55:50 UTC 2021 , Edited by admin on Sat Jun 26 03:55:50 UTC 2021
PRIMARY PUBCHEM
CAS
1841094-17-4
Created by admin on Sat Jun 26 03:55:50 UTC 2021 , Edited by admin on Sat Jun 26 03:55:50 UTC 2021
PRIMARY
FDA UNII
LDX8893L5D
Created by admin on Sat Jun 26 03:55:50 UTC 2021 , Edited by admin on Sat Jun 26 03:55:50 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY